Shares of Sarepta Therapeutics (SRPT) - Get Report were up 3.9% to $29.90 in premarket trading on Wednesday. According to StreetInsider, SunTrust Robinson Humphrey has upped its rating on the stock to buy from hold. The price target is $45. Cambridge, Mass.-based Sarepta focuses on developing RNA-targeted therapeutics for the treatment of rare neuromuscular diseases.
Bellicum Pharmaceuticals (BLCM) - Get Report shares rose 2.4% to $12.80. The Houston firm on Tuesday announced two presentations of preclinical results on its proprietary dual-switch technology for use in CAR-T and TCR product candidates at the American Association for Cancer Research annual meeting in Washington.